AiViva Says Its AIV001 Shows Potential Promise To Treat Post-Surgical Incisional Scarring And Keloids

Interested in investing in AiViva’s campaign? Click here to get started!

 

Scarring can have negative physical, aesthetic, and psychological effects if left untreated. A growing awareness of treatment options and technological advancements has given its treatment industry adoption a boost.

Scars result from injuries, surgeries, illness, burns and acne. Scars form on your skin or inside your body when one heals an injury or trauma.  

Our body’s wound healing process can cause the overproduction of collagen, a protein found in the dermis or second layer of the skin, resulting in raised lumpy scarring or keloids. Keloids tend to grow larger over time and in some cases, reappear after treatment. 

A scar never completely goes away. When it comes to scarring, where it occurs matters. A wound in an area that moves, like your elbow and knee, is more likely to scar. A scar on the face would be harder to heal because one’s face is constantly exposed to the environment.

The Growing Market For Scar and Keloid Treatments 

The keloid and scar treatment market is burgeoning. One reason for this could be an increasing number of accidents, surgeries, and other injuries around the world each year. 

The combined hypertrophic and keloid scar treatment global market was valued at $6.34 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 8.47% from 2022 to 2030. 

Companies like Sanoma Pharmaceuticals SNOA are partnering with e-commerce sites like Amazon.com Inc. AMZN to provide hypertrophic and keloid scar treatment products in the U.S. Partnerships like this are also expected to drive the retail pharmacy segment.

There are reportedly no approved drugs on the market for the prevention of scars following surgery. The appearance of scar may be improved by laser therapy, steroid injections, or silicon sheets. Dermatologists and plastic surgeons may surgically remove a scar to restore function of a body part that may have been restricted by the scar.  

Keloid scars are difficult to get rid of and tend to return after treatment in a majority of cases. Current treatments for keloids include steroidal injections at the scar site, cryosurgery (freezing), keloidectomy (surgical removal), pressure dressings, silicone sheeting and gels and radiation.

While each of these treatment options by themselves, or when combined with others, could help by treating and improving physical appearance and skin sensitivity issues such as itch and pain, a scar never goes away.

How AiViva’s AIV001 Treatment Could Address Scar Formation 

AIV001 is a compound that could address the negative impacts of scarring.

AIV001 has been found to be effective in modulating inflammation and scarring of the skin as well as reducing neovascularization (cell proliferation) associated with some cancers, according to AiViva. 

 The company says it has seen positive signals from its phase I clinical trial of AIV001 for incision-based dermal scarring and wound healing. 

Trial results showed that AIV001 was safe and well tolerated in the local intradermal treatment of incisional wounds and reduced fibrosis through only a single dose with no systemic side effects observed in humans. These results suggest that the intradermal AIV001 treatment could potentially have significant clinical utility by modulating the aberrant scarring associated with fibrosis during the wound-healing process.

“Scarring has been a significant issue that can cause debilitating aesthetic, functional and psychological effects. There are no (Food and Drug Administration) FDA-approved therapeutics for the treatment of post-operative scars, therefore, AIV001 has the potential to be a transformative treatment in this space,” AiViva CEO Diane Tang-Liu said.

About AiViva Biopharma:  

AiViva Biopharma, is a clinical stage biotech company founded in 2015 by four pharmaceutical industry veterans with more than 300 years of combined industry experience. AiViva's founders have demonstrated a successful track record across the full spectrum of drug development and commercialization, in addition to raising capital, and IPOs on the NYSE and NASDAQ.

AiViva was formed with the mission of developing novel, innovative pharmaceutical products through an efficient, risk-mitigated development strategy to address major unmet medical needs.

The company has raised over $30 million in capital so far, including over $10 million raised in 2022. 

AiViva was rated as a top 20 clinical-stage biopharma company by Life Sciences Review in 2022.

Interested in investing in AiViva? Click here.

If you would like to learn more about AiViva, check out its website.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. 

 

Featured photo by Shane on Unsplash